February 2012 Drug Update Information - Pharmacy Benefits ...

More documents

Recommendations

Info

6 mg/24 hours, package of 7 (NDC 00091-6488-21) 6 mg/24 hours, package of 30 (NDC 00091-6488-01) Reason for the Shortage UCB recalled rotigotine transdermal systemss in March, 2008 due to manufacturing problems and crystal formation in the patches. In April, 2010, FDA recommended reformulation of Neupro transdermal systems to prevent crystallization n. Remaining supplies of rotigotine have been depleted. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=395 Source: http://www.a ashp.org Octreotide Injectionn January 4, 2012 Products Affected - Description Octreotide injection, APP 1000 mcg/mL, 5 mL vial (NDC 63323-0379 -05) Octreotide injection, Bedford 50 mcg/mL, 1 mL vial (NDC 55390-0160-10) 100 mcg/ /mL, 1 mL vial (NDC 55390-0161-10) 200 mcg/ /mL, 5 mL vial (NDC 55390-0163-01) 500 mcg/ /mL, 1 mL vial (NDC 55390-0162-10) 1000 mcg/mL, 5 mL vial (NDC 55390-0164 -01) Octreotide injection, Sandoz 200 mcg/ /mL, 5 mL vial (NDC 00781-3165-75) Octreotide injection, Teva 50 mcg/mL, 1 mL vial (NDC 00703-3301-04) 100 mcg/ /mL, 1 mL vial (NDC 00703-3311-04) 500 mcg/ /mL, 1 mL vial (NDC 00703-3321-04) 200 mcg/ /mL, 5 mL vial (NDC 00703-3333-01) 1000 mcg/mL, 5 mL vial (NDC 00703-3343 -01) Reason for the Shortage APP reports that the shortage is due to increased demandd for the product. Ben Venue voluntarily suspendedd all manufacturing and distribution in mid-November, 2011 on a temporary basis for maintenance and requalification off equipment. Product will become available in stages as production resumes. Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products. Availability of products is updated on the Bedford Laboratories website. Sandoz has octreotide on shortage due to delay of raw materials. Teva has octreotide on shortage due to manufacturing delays. Sandostatin LAR presentations from Novartis are not affected by this shortage. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=803 Source: http://www.a ashp.org Lansoprazole Orally Disintegrating Tablets January 4, 2012 Products Affected - Description Lansoprazole orally disintegratin ng tablets, Sandoz 15 mg tablets, 100 count (NDC 00781-5733- -13) 30 mg tablets, 100 count (NDC 00781-5734- -13) Reason for the Shortage Teva discontinued lansoprazole orally disintegrating tablets in February, 2011. 26
Sandoz states the shortage is due to manufacturing issues. The shortage is not affecting regular lansoprazole capsules, which are readily available from multiple manufacturers. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=839 Source: http://www.a ashp.org Acyclovir Capsules and Tablets January 20, 2012 Products Affected - Description Acyclovir capsules and tablets, Apotex 200 mg capsules, 1000 count (NDC 60505-0042-06) 400 mg tablets, 100 count (NDC 60505-5306-01) 400 mg tablets, 10000 count (NDC 60505-5306-08) 800 mg tablets, 100 count (NDC 60505-5307-01) 800 mg tablets, 10000 count (NDC 60505-5307-08) Acyclovir capsules and tablets, Ranbaxy 400 mg tablets, 100 count (NDC 63304-0504-01) 800 mg tablets, 100 count (NDC 63304-0505-01) 200 mg capsules, 1000 count (NDC 63304-0652-01) 200 mg capsules, 5000 count (NDC 63304-0652-05) - discontinued Acyclovir capsules and tablets, Teva 200 mg capsules, 1000 count (NDC 00093-8940-01) 200 mg capsules, 1000 count, unit dose (NDC 00093-8940-93) 200 mg capsules, 5000 count (NDC 00093-8940-05) 400 mg tablets, 100 count (NDC 00093-8943-01) 400 mg tablets, 100 count, unit-dose (NDC 00093-8943- -93) 400 mg tablets, 500 count (NDC 00093-8943-05) 800 mg tablets, 100 count (NDC 00093-8947-01) 800 mg tablets, 100 count, unit-dose (NDC 00093-8947- -93) 800 mg tablets, 500 count (NDC 00093-8947-05) Reason for the Shortage Apotex has halted manufacturing due to an FDA audit. Ranbaxy has acyclovir capsules and tablets on back order due to a raw materials shortage. Teva could not provide a reason for the shortage. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=591 Source: http://www.a ashp.org Cefpodoxime January 24, 2012 Products Affected - Description Cefpodoxime, Aurobindo 100 mg tablet, 20 count (NDC 65862-0095-20) 200 mg tablet, 20 count (NDC 65862-0096-20) 50 mg/5 mL, 50 mL suspension (NDC 65862-0140-50) 50 mg/5 mL, 100 mL suspensionn (NDC 65862-0140-01) ) 100 mg/5 mL, 50 mL (NDC 65862-0141-50) 100 mg/mL, 100 mL suspension (NDC 65862-0141-01) Cefpodoxime, Ranbaxy 100 mg tablet, 20 count (NDC 63304-0520-20) 200 mg tablet, 20 count (NDC 63304-0521-20) 27
Page 1 and 2: February 2012 Drug Information Upda
Page 3 and 4: GENERIC DRUG NAME GENERIC APPROVAL
Page 5 and 6: CICLOPIROX/ TOPICAL PEDIPIROX-4 New
Page 7 and 8: [Posted 01/09/2012] ISSUE: Novartis
Page 9 and 10: Studies Article Link: http://www.fd
Page 11 and 12: the use of XARELTO® (rivaroxaban),
Page 13 and 14: acteria. The Food and Drug Administ
Page 15 and 16: Statins raise risk of Type 2 diabet
Page 17 and 18: The Million Women Study, a U.K. pro
Page 19 and 20: Azithromycin 250 mg tablets, 1 card
Page 21 and 22: RECALLING FIRM/MANUFACTURE Recallin
Page 23 and 24: Recalling Firm: Pfizer Us Pharmaceu
Page 25: 250 mg, 100 count (NDC 00591-3969-0
Page 29 and 30: 5 mL ampule (NDC 10019-0033-72) 20
Page 31 and 32: Article Link: http://www.ashp.org/D
Page 33 and 34: Lidocaine 2% (with epinephrine 1:10
Page 35 and 36: Source: http://www.a ashp.org Halop
Page 37 and 38: ecome unavailable for an extended t
Page 39 and 40: American Regent resumed manufacturi
Page 41 and 42: Trandate tablets, Prometheus 100 mg
Page 43 and 44: Article link: http://www.ashp.org/D
Page 45 and 46: Bedford Laboratories has multiple p
Page 47 and 48: Thiothixene capsules, Mylan 2 mg ca
Page 49 and 50: 20 mL vials (NDC 10019-0905-03) - d
Page 51 and 52: 500 mg extended release, 500 count
Page 53 and 54: 1 mg/mL, 4 mL vial (NDC 25021-0781-
Page 55 and 56: West-Ward states the shortage is du
Page 57 and 58: 150 mL bottle (NDC 63304-0954-02) C

February 2012 Drug Update Information - Pharmacy Benefits ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?